These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 16128684

  • 1. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 2. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA.
    J Rheumatol; 2003 Dec 01; 30(12):2557-62. PubMed ID: 14719194
    [Abstract] [Full Text] [Related]

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 01; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP.
    Gastroenterol Clin Biol; 2002 Nov 13; 26(11):973-9. PubMed ID: 12483127
    [Abstract] [Full Text] [Related]

  • 6. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep 13; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

  • 7. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec 13; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 8. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 9. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 10. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ.
    Am J Gastroenterol; 2001 Mar 01; 96(3):722-9. PubMed ID: 11280541
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep 01; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 12. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 13. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 14. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M, Italian Multicentric Study Group on Infliximab.
    Dig Liver Dis; 2005 Aug 01; 37(8):577-83. PubMed ID: 15886081
    [Abstract] [Full Text] [Related]

  • 15. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul 01; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 16. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr 01; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 17. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 18. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.
    Colorectal Dis; 2005 Mar 01; 7(2):164-8. PubMed ID: 15720356
    [Abstract] [Full Text] [Related]

  • 19. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL, García-Paredes J, Cruz Santamaria DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, Díaz-Rubio M.
    Rev Esp Enferm Dig; 2002 May 01; 94(5):269-79. PubMed ID: 12474335
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2009 Oct 01; 30(7):749-56. PubMed ID: 19583709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.